{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T13:57:04Z","timestamp":1770040624832,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003615.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000}}],"reference-count":67,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003615.pub4","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T08:41:51Z","timestamp":1540284111000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review"],"prefix":"10.1002","volume":"2018","author":[{"given":"Sarah J","family":"Nevitt","sequence":"first","affiliation":[{"name":"University of Liverpool; Department of Biostatistics; Block F, Waterhouse Building 1-5 Brownlow Hill Liverpool UK L69 3GL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catrin","family":"Tudur Smith","sequence":"additional","affiliation":[{"name":"University of Liverpool; Department of Biostatistics; Block F, Waterhouse Building 1-5 Brownlow Hill Liverpool UK L69 3GL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre for Research and Education, Lower Lane Fazakerley Liverpool Merseyside UK L9 7LJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD003615.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0920-1211(92)90099-F","article-title":"Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up","volume":"11","author":"Aikia","year":"1992","journal-title":"Epilepsy Research"},{"issue":"3","key":"10.1002\/14651858.CD003615.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0920-1211(97)00024-7","article-title":"A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy","volume":"27","author":"Bill","year":"1997","journal-title":"Epilepsy Research"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD003615.pub4-BIB0003|cit3","first-page":"265","article-title":"Oxcarbazepine is at least as effective and well-tolerated as phenytoin with a superior safety profile over long-term treatment in patients with partial seizures","volume":"44","author":"D'Souza","year":"2003","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD003615.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.yebeh.2007.02.011","article-title":"How reliable is early treatment response in predicting long-term seizure outcome?","volume":"10","author":"Schmidt","year":"2007","journal-title":"Epilepsy & Behavior"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD003615.pub4-BIB0005|cit5","first-page":"265","article-title":"Oxcarbazepine is at least as effective and well-tolerated as phenytoin with a superior safety profile over long-term treatment in patients with partial seizures","volume":"44","author":"D'Souza","year":"2003","journal-title":"Epilepsia"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003615.pub4-BIB0006|cit6","first-page":"148","article-title":"Better seizure control and tolerability over the long term with oxcarbazepine (Trileptal (R)) monotherapy compared with phenytoin in newly diagnosed children and adolescents with partial and generalised tonic-clonic seizures","volume":"44","author":"Guerreiro","year":"2003","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD003615.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0920-1211(97)00025-9","article-title":"A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy","volume":"27","author":"Guerreiro","year":"1997","journal-title":"Epilepsy Research"},{"issue":"4","key":"10.1002\/14651858.CD003615.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.yebeh.2007.02.011","article-title":"How reliable is early treatment response in predicting long-term seizure outcome?","volume":"10","author":"Schmidt","year":"2007","journal-title":"Epilepsy & Behavior"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD003615.pub4-BIB0009|cit9","first-page":"272","article-title":"Long-term oxcarbazepine therapy in children is at least as effective as and better tolerated than phenytoin","volume":"44","author":"Sturm","year":"2003","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD003615.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-0404.1995.tb00461.x","article-title":"Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy","volume":"92","author":"Sabers","year":"1995","journal-title":"Acta Neurologica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD003615.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1528-1157.1999.tb00748.x","article-title":"The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations","volume":"40","author":"Annegers","year":"1999","journal-title":"Epilepsia"},{"issue":"8","key":"10.1002\/14651858.CD003615.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2165\/00148581-200305080-00006","article-title":"Oxcarbazepine: a review of its use in children with epilepsy","volume":"5","author":"Bang","year":"2003","journal-title":"Paediatric Drugs"},{"issue":"12","key":"10.1002\/14651858.CD003615.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1212\/WNL.54.12.2245","article-title":"Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial","volume":"54","author":"Beydoun","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD003615.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1528-1157.1992.tb02330.x","article-title":"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin","volume":"33","author":"Carl","year":"1992","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD003615.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0920-1211(96)01013-3","article-title":"A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy","volume":"26","author":"Christe","year":"1997","journal-title":"Epilepsy Research"},{"issue":"8968","key":"10.1002\/14651858.CD003615.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: results from the National General Practice Study of Epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD003615.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures","volume":"22","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1981","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD003615.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1989","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD003615.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0920-1211(89)90070-3","article-title":"A double blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy","volume":"3","author":"Dam","year":"1989","journal-title":"Epilepsy Research"},{"issue":"1","key":"10.1002\/14651858.CD003615.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1155\/1990\/917164","article-title":"Metabolic characteristics of oxcarbazepine (Trileptal) and their beneficial implications for enzyme induction and drug interactions","volume":"3","author":"Faigle","year":"1990","journal-title":"Behaviour Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003615.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0890-6238(92)90181-R","article-title":"Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study","volume":"6","author":"Gladstone","year":"1992","journal-title":"Reproductive Toxicology"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00003495-199243060-00007","article-title":"Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders","volume":"43","author":"Grant","year":"1992","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 - 1984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0025|cit25","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/01.wnl.0000252807.38124.a3","article-title":"How common are the \"common\" neurologic disorders?","volume":"68","author":"Hirtz","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD003615.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1528-1157.1998.tb01167.x","article-title":"Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy","volume":"39","author":"ILAE Commission on Antiepileptic Drugs","year":"1998","journal-title":"Epilepsia"},{"issue":"7","key":"10.1002\/14651858.CD003615.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","article-title":"ILAE treatment guidelines: evidence based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"47","author":"Glauser","year":"2006","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1528-1157.1983.tb04893.x","article-title":"Natural history of epileptic seizures","volume":"24","author":"Juul-Jenson","year":"1983","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"11 Suppl 4","key":"10.1002\/14651858.CD003615.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.60.11_suppl_4.S2","article-title":"Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy","volume":"60","author":"Kwan","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0032|cit32","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/1531-8249(200012)48:6<833::AID-ANA3>3.0.CO;2-U","article-title":"Factors predicting prognosis of epilepsy after presentation with seizures","volume":"48","author":"MacDonald","year":"2000","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0034|cit34","volume-title":"Idiopathic Generalised Epilepsies: Clinical, Experimental and Genetic","author":"Malfosse","year":"1994"},{"issue":"3","key":"10.1002\/14651858.CD003615.pub4-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001030","article-title":"Carbamazepine versus valproate monotherapy for epilepsy","author":"Marson","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD003615.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM198507183130303","article-title":"Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures","volume":"313","author":"Mattson","year":"1985","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003615.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.04.022","article-title":"Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts","volume":"81","author":"Meador","year":"2008","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0038|cit38","unstructured":"Murray CJL Lopez AD World Health Organization. Global comparative assessments in the health sector: disease burden, expenditures and intervention packages apps.who.int\/iris\/handle\/10665\/41177"},{"issue":"12","key":"10.1002\/14651858.CD003615.pub4-BIB0039|cit39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011412.pub3","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","author":"Nevitt","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003615.pub4-BIB0040|cit40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001911.pub3","article-title":"Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review","author":"Nevitt","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD003615.pub4-BIB0041|cit41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001031.pub4","article-title":"Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review","author":"Nevitt","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD003615.pub4-BIB0042|cit42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001769.pub4","article-title":"Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review","author":"Nevitt","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD003615.pub4-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001904.pub4","article-title":"Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review","author":"Nevitt","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1528-1167.2009.02481.x","article-title":"Estimation of the burden of active and life-time epilepsy: a meta-analytic approach","volume":"51","author":"Ngugi","year":"2010","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0045|cit45","unstructured":"National Institute for Health and Care Excellence The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care www.nice.org.uk\/guidance\/cg137"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0046|cit46","unstructured":"Nolan SJ Sutton L Marson A Tudur Smith C Consistency of outcome and statistical reporting of time-to-event data: the impact on Cochrane Reviews and meta-analyses in epilepsy 21st Cochrane Colloquium: Better Knowledge for Better Health, Quebec City 2013 114 5"},{"issue":"1","key":"10.1002\/14651858.CD003615.pub4-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002217.pub2","article-title":"Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures","author":"Nolan","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD003615.pub4-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012065.pub2","article-title":"Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review","author":"Nolan","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD003615.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/(SICI)1096-8628(19970110)68:1<18::AID-AJMG4>3.0.CO;2-U","article-title":"Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications","volume":"68","author":"Nulman","year":"1997","journal-title":"American Journal of Medical Genetics"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1474-4422(05)70172-1","article-title":"Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study","volume":"4","author":"Olafsson","year":"2005","journal-title":"Lancet Neurology"},{"issue":"24","key":"10.1002\/14651858.CD003615.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0052|cit52","unstructured":"Pohlmann H Personal communication"},{"issue":"5","key":"10.1002\/14651858.CD003615.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/jnnp.61.5.433","article-title":"Epidemiology of the epilepsies","volume":"61","author":"Sander","year":"1996","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD003615.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.0013-9580.2004.455005.x","article-title":"The use of anti-epileptic drugs - principles and practice","volume":"45","author":"Sander","year":"2004","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD003615.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1212\/WNL.52.4.732","article-title":"Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures","volume":"52","author":"Schachter","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003615.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD003615.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5070\/D32197W4T4","article-title":"Phenytoin in cutaneous medicine: its uses, mechanisms and side effects","volume":"9","author":"Scheinfeld","year":"2003","journal-title":"Dermatology Online Journal"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0058|cit58","unstructured":"StataCorp Stata Statistical Software: Release 14 2015"},{"issue":"2","key":"10.1002\/14651858.CD003615.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1212\/WNL.49.2.542","article-title":"Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study","volume":"49","author":"Tennis","year":"1997","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD003615.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1745-6215-8-34","article-title":"Multiple treatment comparisons in epilepsy monotherapy trials","volume":"5","author":"Tudur Smith","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0061|cit61","article-title":"Guidelines for the clinical management of adults with poorly controlled epilepsy","volume-title":"National Society of Epilepsy guidelines","author":"Wallace","year":"1997"},{"issue":"2","key":"10.1002\/14651858.CD003615.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00023210-200115020-00005","article-title":"Oxcarbazepine: an update of its efficacy in the management of epilepsy","volume":"15","author":"Wellington","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD003615.pub4-BIB0063|cit63","first-page":"339","article-title":"Phenytoin: clinical use","volume-title":"Antiepileptic Drugs","author":"Wilder","year":"1995"},{"issue":"2","key":"10.1002\/14651858.CD003615.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2753.2000.00236.x","article-title":"Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials","volume":"6","author":"Williamson","year":"2000","journal-title":"Journal of Evaluation in Clinical Practice"},{"issue":"22","key":"10.1002\/14651858.CD003615.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time-to-event outcomes","volume":"21","author":"Williamson","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003615.pub4-BIB0066|cit66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003615.pub2","article-title":"Oxcarbazepine versus phenytoin monotherapy for epilepsy","author":"Muller","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD003615.pub4-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003615.pub3","article-title":"Oxcarbazepine versus phenytoin monotherapy for epilepsy","author":"Nolan","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003615.pub4\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:23:21Z","timestamp":1628544201000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003615.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":67,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003615.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]}}}